Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant Volume

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-95
SponsorGermans Trias i Pujol Hospital

About this trial

The goal of this observational study is demonstrate that a novel artificial intelligence based software for the quantification of the mitral regurgitation on 3-dimensional transesophageal echocardiography (3D CFQ) is more reproducible and accurate than the conventional assessment of mitral regurgitation performed with 2-dimensional echocardiography. The main question aims to answer is to demonstrate the agreement between 3D-CFQ measurement of the mitral regurgitant volume and the cardiac magnetic resonance measurement of the regurgitant volume is better than the agreement between 2-dimensional echocardiography and cardiac magnetic resonance. If this is demonstrated, we would like to test the accuracy of this tool to be applied in acute settings such as transcatheter interventions to decide the therapy to follow.

Participants will undergo clinically indicated transesophageal echocardiography to characterize the mechanism and severity of mitral regurgitation and to cardiac magnetic resonance to be used as reference stadard to define the mitral regurgitation severity.

Eligibility criteria

Qualifiers

Patients with at least moderate mitral regurgitation of any etiology

Patients with good transesophageal echocardiography image quality

Disqualifiers

Patients with prior transcatheter or surgical mitral valve intervention

Patients with contraindications for transesophageal echocardiography or cardiac magnetic resonance

Trial design

Treatments tested in this trial

  • analysis of the performance of an artificial intelligenced based software for analysis of 3D tranesophageal echocardiography data

Treatment groups

200 Participants
are divided into 1 treatment group

Sponsors and collaborators